Corvus Pharma Com (CRVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2019 | 12-2018 | 12-2017 | 12-2016 | 12-2015 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 5,154 | 39,196 | 45,106 | 5,050 | 4,105 |
| Marketable Securities | 72,828 | 75,401 | 44,949 | 129,846 | 90,281 |
| TOTAL | $79,344 | $115,589 | $91,234 | $136,033 | $95,663 |
| Non-Current Assets | |||||
| PPE Net | 1,462 | 2,180 | 2,672 | 3,248 | 1,845 |
| Other Non-Current Assets | 2,840 | 463 | 869 | 869 | 951 |
| TOTAL | $4,302 | $2,643 | $3,541 | $4,117 | $2,796 |
| Total Assets | $83,646 | $118,232 | $94,775 | $140,150 | $98,459 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,448 | 1,998 | 3,454 | 1,900 | 1,575 |
| Accrued Expenses | 6,899 | 5,029 | 5,515 | 4,044 | 1,495 |
| TOTAL | $10,225 | $7,027 | $8,969 | $5,944 | $3,070 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 2,310 | 869 | 971 | 1,405 | 710 |
| TOTAL | $2,310 | $869 | $971 | $1,405 | $710 |
| Total Liabilities | $12,535 | $7,896 | $9,940 | $7,349 | $3,780 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 29,327 | 29,327 | 21,066 | 20,933 | 20,406 |
| Common Shares | 3 | 3 | 2 | 2 | N/A |
| Retained earnings | -217,145 | -170,473 | -123,534 | -67,871 | -31,496 |
| Other shareholders' equity | 29 | -34 | -41 | -39 | 125,735 |
| TOTAL | $71,111 | $110,336 | $84,835 | $132,801 | $94,679 |
| Total Liabilities And Equity | $83,646 | $118,232 | $94,775 | $140,150 | $98,459 |